American Society Of Hematology
Most patients with sickle cell disease not prescribed disease-modifying therapy
The underutilization of disease-modifying therapy by people with sickle cell disease is “persistent and alarming,” according to an analysis of real-world data.
Q&A: Lower blood thinner dose can reduce bleeding risk
Reduced dosing of direct oral anticoagulants may offer comparable efficacy as full dosing for adults with venous thromboembolism history while decreasing bleeding risk and reducing health care utilization, according to study results.
Insurers reject up to one-third of new specialty oral blood cancer prescriptions
SAN DIEGO — Insurers rejected one-third of new prescriptions for specialty oral anticancer medications ordered for patients with blood cancers, according to retrospective data presented at ASH Annual Meeting and Exposition. Patients with commercial insurance and Medicaid had prescriptions rejected more often than patients with Medicare.
Literature review shows no link between sickle cell trait, sudden death
Sickle cell trait does not cause individuals to die of physical exertion or heat-related injuries without rhabdomyolysis, according to a findings of a systematic literature review.
Real-world outcomes with bispecific T-cell engagers in lymphoma worse than pivotal trials
SAN DIEGO — Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings achieved worse survival outcomes than those who received the agents in pivotal trials.
In-clinic mental health, cognitive screening can benefit patients with sickle cell disease
SAN DIEGO — Psychological and neurocognitive screening may help monitor mental and physical health among people with sickle cell disease, according to a speaker at ASH Annual Meeting and Exposition.
Optimizing physician mentorship from selection to ‘sunset’
SAN DIEGO — Sustaining a successful mentor-mentee relationship requires compatibility in terms of skillsets and goals, according to a speaker at ASH Annual Meeting and Exposition.
Tandem non-cryopreserved CAR-T exhibits ‘favorable’ activity in advanced DLBCL
SAN DIEGO — A rapidly delivered tandem chimeric antigen receptor T-cell therapy produced favorable outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma, according to interim results of a phase 2 trial.
First-line regimen improves PFS in chronic lymphocytic leukemia
SAN DIEGO — A multidrug combination significantly improved survival for certain patients with leukemia compared with standard chemoimmunotherapy, according to results of the randomized phase 3 AMPLIFY study.
AI in hematology: ‘The good, the bad and the ugly’
SAN DIEGO — The increased use of AI in health care has generated tremendous excitement for its potential to guide treatment decision-making, improve outcomes and increase efficiency.